Form 4: Invivyd CFO William E. Duke Reports Stock Option and Restricted Stock Unit Grants

Chief Financial Officer William E. Duke of Invivyd, Inc. reports the acquisition of stock options and restricted stock units.

Summary

• William E. Duke, CFO of Invivyd, Inc., filed a Form 4 on February 19, 2025, reporting transactions related to the company's equity securities.
• On February 15, 2025, Duke was granted stock options to purchase 950,000 shares of common stock at an exercise price of $1.61.
• These options vest over a three-year period, with 1/36th of the shares vesting monthly starting one month after the grant date, contingent upon continuous service.
• Duke also received 300,000 restricted stock units (RSUs), each representing a right to receive one share of common stock.
• These RSUs vest over an eighteen-month period, with one-third vesting every six months following the grant date, also subject to continuous service.
• Shares of common stock will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation.

Positives

• The grants of stock options and RSUs to the CFO align his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.

Industry Context

The granting of stock options and RSUs is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech industry, often used to attract and retain talent.
• Vesting schedules, such as the three-year monthly vesting for the stock options and eighteen-month semi-annual vesting for the RSUs, are typical in similar companies.
• Comparable companies like Moderna or BioNTech also utilize equity-based compensation to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of aligning management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates